Saxenda: A Breakthrough in Weight Loss Drugs for Children's Health

Wednesday, 11 September 2024, 16:20

Saxenda revolutionizes weight loss for children, showing significant reduction in body mass index. This groundbreaking drug is a beacon of hope in children's health as it aids those aged six to eleven in managing obesity effectively.
Businessinsider
Saxenda: A Breakthrough in Weight Loss Drugs for Children's Health

Saxenda Shows Promise in Children's Health

Danish drugmaker Novo Nordisk's weight loss drug Saxenda has helped children aged six to eleven reduce their body mass index significantly, according to trial results released on Tuesday. The results indicated that children receiving daily injections of Saxenda saw a 5.8% average cut in BMI during the 56-week trial, and an impressive 7.4% average reduction compared to the placebo group.

Importance of Saxenda in Weight Loss

BMI, while frequently debated as an indicator of health, serves as a crucial measurement in assessing the effectiveness of weight loss solutions. Notably, there are currently no FDA-approved medications for treating obesity in children. The FDA had previously approved Saxenda, which contains liraglutide, for teenagers in 2020 and adults in 2014. In light of these new findings, Novo Nordisk plans to pursue FDA approval for Saxenda in younger children, potentially transforming children's health strategies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest insights and trends from around the world. Stay informed and elevate your global perspective effortlessly.

Subscribe